Dalmau et al. 99. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-8. https://doi.org/10.1016/S1474-4422(08)70224-2
https://doi.org/10.1016/S1474-4422(08)70...
(2008) |
100 |
95 (95%) |
92 (92%) |
55 (55%) |
Florance et al.1010. Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66(1):11-8. https://doi.org/10.1002/ana.21756
https://doi.org/10.1002/ana.21756...
(2009) |
32 |
31 (96.9%) |
25 (78.1%) |
10 (31.2%) |
Irani et al.1111. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133(Pt 6):1655-67. https://doi.org/10.1093/brain/awq113
https://doi.org/10.1093/brain/awq113...
(2010) |
44 |
30 (68.2%) |
35 (79.5%) |
5 (11.4%) |
Titulaer et al.44. Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iisuka T et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157-65. https://doi.org/10.1016/S1474-4422(12)70310-1
https://doi.org/10.1016/S1474-4422(12)70...
(2013) |
557 |
418/532 (78.6%) |
432/482 (89.6%) |
180/540 (33.3%) |
Viaccoz et al.1212. Viaccoz A, Desestret V, Ducray F, Picard G, Cavillon G, Rogemond V et al. Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology. 2014;82(7):556-63. https://doi.org/10.1212/WNL.0000000000000126
https://doi.org/10.1212/WNL.000000000000...
(2014) |
71 |
56/62 (90.3%) |
47/61 (77%) |
25/69 (36.2%) |
Zekeridou et al.1313. Zekeridou A, Karantoni E, Viaccoz A, Ducray F, Gitiaux C, Villega F et al. Treatment and outcome of children and adolescents with N-methyl-D-aspartate receptor encephalitis. J Neurol. 2015;262(8):1859-66. https://doi.org/10.1007/s00415-015-7781-9
https://doi.org/10.1007/s00415-015-7781-...
(2015) |
36 |
32/35 (91.4%) |
32/35(91.4%) |
11/35 (31.4%) |
Sartori et al.77. Sartori S, Nosadini M, Cesaroni E, Falsaperla R, Capovilla G, Beccaria F et al. Paediatric anti-N-methyl-D-aspartate receptor encephalitis: the first Italian multicenter case series. Eur J Paediatr Neurol. 2015;19(4):453-63. https://doi.org/10.1016/j.ejpn.2015.02.006
https://doi.org/10.1016/j.ejpn.2015.02.0...
(2015) |
20 |
9/16 (56.3%) |
19/19 (100%) |
9 (45%) |
Wang et al.55. Wang W, Li JM, Hu FY, Wang R, Hong Z, He L et al. Anti-NMDA receptor encephalitis: clinical characteristics, predictors of outcome and the knowledge gap in southwest China. Eur J Neurol. 2016;23(3):621-9. https://doi.org/10.1111/ene.12911
https://doi.org/10.1111/ene.12911...
(2016) |
51 |
32 (62.7%) |
42/49 (85.7%) |
20/50 (40%) |
Wright et al.1414. Wright S, Hacohen Y, Jacobson L, Agrawal S, Gupta R, Philip S et al. N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children Arch Dis Child. 2015;100(6):521-6. https://doi.org/10.1136/archdischild-2014-306795
https://doi.org/10.1136/archdischild-201...
(2015) |
31 |
13/29 (44.8%) |
28/30 (93.3%) |
11 (35.5%) |
Nagappa et al. 1515. Nagappa M, Bindu PS, Mahadevan A, Sinha S, Mathuranath PS, Taly AB. Clinical features, therapeutic response, and follow-up in pediatric anti-n-methyl-D-aspartate receptor encephalitis: experience from a tertiary care university hospital in India. Neuropediatrics. 2016;47(1):24-32. https://doi.org/10.1055/s-0035-1569464
https://doi.org/10.1055/s-0035-1569464...
(2016) |
13 |
2 (15.4%) |
13 (100%) |
2 (15.4%) |
Zhang et al. 1616. Zhang L, Wu MQ, Hao ZL, Chiang SM, Shuang K, Lin MT et al. Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis: A systematic review of reported cases. Epilepsy Behav. 2017;68:57-65. https://doi.org/10.1016/j.yebeh.2016.12.019
https://doi.org/10.1016/j.yebeh.2016.12....
(2017) |
432 |
186/320 (58.1%) |
240/281 (85.4%) |
137/342 (40%) |
Our series |
30 |
13 (43.3%) |
28 (93.3%) |
19 (63.3%) |